How can we improve prognostic models in renal cell carcinoma?

Carlo Buonerba, Matteo Ferro, Francesco Perri, Giuseppe Calderoni, Pina Mambella, Pasqualina Giordano, Prisco Piscitelli, Vittorino Montanaro, Michele Aieta, Giuseppe Di Lorenzo

Research output: Contribution to journalArticlepeer-review


The therapeutic improvements in renal cell carcinoma brought about by the transition from the 'cytokine era' to the 'targeted agents era', have not affected the peculiar prognostic heterogeneity of the disease, nor have they diminished the importance of risk group classification based on easily assessable and commonly available laboratory and clinical variables. In the landmark study conducted by Motzer et al. before biological agents were available, the median survival of patients in the good prognosis group was 20 months, while the patients in the poor-risk group had a median survival time of only 4 months. With the introduction of anti-VEGF agents, overall survival has approximately doubled in all risk classes. In a population-based analysis of 670 patients treated with anti-VEGF agents, either in the first-line setting or in the second-line setting after cytokines, stratification according to the Database Consortium model showed that patients in the favorable risk group had a median overall survival of 43.2 months, while patients in the poor-risk group had a median overall survival of 7.8 months.

Original languageEnglish
Pages (from-to)1281-1283
Number of pages3
JournalExpert Opinion on Pharmacotherapy
Issue number9
Publication statusPublished - Jun 1 2015


  • Biological therapy
  • Concordance index
  • Kidney cancer
  • Prognostic models

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'How can we improve prognostic models in renal cell carcinoma?'. Together they form a unique fingerprint.

Cite this